|
|
Vaccine Detail
|
PolyPEPI1018 CRC Vaccine |
| Vaccine Information |
- Vaccine Name: PolyPEPI1018 CRC Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: Subunit vaccine
- Status: Clinical trial
- Host Species for Licensed Use: None
- Antigen: cancer testis antigens (CTAs) (NCT03391232; NCIT_C154278)
- Immunization Route: subcutaneous injection
- Description: The vaccine contains 6 synthetic peptides mixed with the adjuvant Montanide™. The peptides were selected to induce T cell responses against 12 dominant epitopes from 7 cancer testis antigens (CTAs), which are the most frequently expressed CTAs in colorectal cancer. The 6 peptides were optimized to induce long lasting CRC specific T cell responses. (NCT03391232) Colorectal cancer peptide vaccine PolyPEPI1018 potentially elicits a cytotoxic T-lymphocyte response against colorectal tumors expressing the CTAs associated with the vaccine, which may result in a reduction in tumor cell proliferation. (NCIT_C154278)
|
| Host Response |
|
|
| References |
NCIT_C154278: Colorectal Cancer Peptide Vaccine PolyPEPI1018 [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C154278]
NCT03391232: PolyPEPI1018 Vaccine and CDx for the Treatment of Metastatic Colorectal Cancer (OBERTO) (OBERTO) [https://clinicaltrials.gov/study/NCT03391232]
|
|
